Association of Platelet Count Detected by Novel Nano Probe with Prognosis After Initial Chemotherapy in Patients with Acute Myeloid Leukemia

Abstract

Objective: To analyze the correlation between platelet count changing and the newly diagnosed patients with acute myeloid leukemia (AML) after initial induction of chemotherapy for the first time, and to explore the prognostic indicators affecting AML. Methods: 253 AML patients who received explicit diagnosis and treatment as AML. Platelet counts were detected by a near-infrared fluorescence nano probe based upon tirofiban, a clinically approved small-molecule glycoprotein IIb/IIIa inhibitor (GPIIb/IIIa). Results: Hemorrhage, platelet transfusion during chemotherapy and increased the platelet count after a course of treatment are risk factors for complete remission after chemotherapy, in which platelet count detected by nano probe after chemotherapy is an independent risk factor for complete remission in AML patients. Conclusion: Using nano probe to detect platelet by using small-molecule glycoprotein IIb/IIIa inhibitor (GPIIb/IIIa) can significantly improve descision making in AML patient in comparison to other traditional methods. In addition, we found that the prognosis of patients with newly diagnosed AML patients with increased platelet count after induction chemotherapy for the first time is better than no increase.